# OnCo record cup-unfavourable (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/cup-unfavourable/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "cup-unfavourable" ;
  schema:name "Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)"@en ;
  schema:alternateName "Unfavourable-risk CUP"@en, "Poor-prognosis CUP"@en, "CUP adenocarcinoma with liver or multiple metastases"@en, "Non-specific CUP"@en ;
  schema:description "Unfavourable cancer of unknown primary is the large majority of cases, where a metastatic adenocarcinoma or poorly differentiated carcinoma fits no recognised pattern and its origin cannot be found. Treatment has long been general-purpose platinum chemotherapy, but CUPISCO showed that matching drugs to the tumour's genetic faults after short chemotherapy holds the disease longer."@en ;
  schema:url <https://onco.cc/cancers/cup-unfavourable/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Cancer_of_unknown_primary_origin> ;
  schema:citation <https://doi.org/10.1016/S0140-6736(24)00814-6>, <https://doi.org/10.1016/j.annonc.2022.11.013>, <https://en.wikipedia.org/wiki/Cancer_of_unknown_primary_origin> ;
  onco:tag "subtype-page", "site-agnostic" ;
  onco:related <https://onco.cc/cancers/cup-favourable-subsets/>, <https://onco.cc/cancers/cancer-of-unknown-primary/>, <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:technologies <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/technologies/platinum/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/her2/>, <https://onco.cc/targets/braf/>, <https://onco.cc/targets/ntrk/>, <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/gemcitabine-cisplatin/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/> ;
  onco:terms <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/msi/>, <https://onco.cc/terms/ihc/>, <https://onco.cc/terms/primary-tumour/> ;
  onco:trials <https://onco.cc/trials/cupisco/>, <https://onco.cc/trials/nct07761429/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-cupisco-molecularly-guided-therapy-cup-lancet-2024/>, <https://onco.cc/key-papers/paper-esmo-cancer-of-unknown-primary-guideline-ann-oncol-2023/>, <https://onco.cc/key-papers/paper-hayashi-site-specific-vs-empirical-chemotherapy-cup-jco-2019/> ;
  onco:pipeline <https://onco.cc/trials/cupisco/>, <https://onco.cc/trials/nct07761429/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:standardOfCare <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/gemcitabine-cisplatin/>, <https://onco.cc/trials/cupisco/>, <https://onco.cc/technologies/platinum/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/nct07761429/>, <https://onco.cc/bottlenecks/b-palliative/> .